Analysis on Pfizer’s COVID-19 Vaccine Distribution Leaves Many Healthcare Workers Unprotected
Countrywide, hospitals are preparing for the first 3.2 million shipments of Pfizer’s COVID-19 vaccine. The first round of shipments will be distributed to five government agencies before Moderna’s vaccine hits the market. State’s will have final say on...
World Health Organization (WHO) Considers E-Vaccination Certificates
Today (12/3) a World Health Organization (WHO) medical expert divulged the organization’s discussions on an e-vaccination certificate for recovered COVID-19 travelers. The WHO has previously expressed concerns regarding "immunity passports" recommendations,...
Center for Disease Control (CDC) Adjusts Quarantine Guidelines
The U.S. Center for Disease Control (CDC) provided an alternative option to a 14-day quarantine standard, advising that patients with a negative test quarantine for 7 days, and those asymptomatic with no test results for 10. The adjustments were made in hopes to...
Review of Johnson & Johnson’s COVID-19 Vaccine Underway
After finding that the Johnson & Johnson vaccines triggered antibody cell formation to fight COVID-19, the European Medicines Agency (EMA) began to review the drug for emergency use authorization (EUA). Meanwhile, the company’s rivals Moderna and...
Moderna Requests FDA Emergency Use Authorization for mRNA-1273
Today (11/30) Moderna announced their plans to seek emergency use authorization from the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccine candidate that reported a 94.1% efficacy rate. The study, that evaluated over 30,000 U.S participants,...
FDA Breakthrough Device List Includes Breast Cancer Treatment
A wide variety of medical technology devices are being more rapidly reviewed and tested for patient use through the U.S. Food and Drug Administration (FDA) Breakthrough Device List. Among the list of innovations are two breast cancer diagnostic tests along...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com